{"id":745076,"date":"2015-11-15T00:00:00","date_gmt":"2015-11-15T00:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/"},"modified":"2025-11-07T01:24:48","modified_gmt":"2025-11-07T06:24:48","slug":"merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/","title":{"rendered":"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae"},"content":{"rendered":"<p class=\"bwalignc\">       Patients with Compensated Liver Cirrhosis Among Most        Difficult-to-Treat     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of results from an integrated analysis<br \/>\n      of patients with compensated liver cirrhosis (Child-Pugh class A) from<br \/>\n      six Phase 2 and 3 clinical trials evaluating the efficacy and safety of<br \/>\n      the investigational once-daily tablet elbasvir\/grazoprevir<sup>1<\/sup><br \/>\n      (50mg\/100mg) with or without ribavirin (RBV) in patients with chronic<br \/>\n      hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from<br \/>\n      the full analysis set (FAS) (n=402) demonstrate that treatment-na\u00efve<br \/>\n      patients with compensated liver cirrhosis who received<br \/>\n      elbasvir\/grazoprevir with or without RBV for 12 weeks achieved sustained<br \/>\n      virologic response 12 weeks after the completion of treatment (SVR12, or<br \/>\n      virologic cure) at rates of 90 percent (28\/31) and 98 percent (135\/138),<br \/>\n      respectively. Treatment-experienced patients who received<br \/>\n      elbasvir\/grazoprevir with or without RBV for 12 weeks achieved virologic<br \/>\n      cure rates of 91 percent (74\/81) and 89 percent (48\/54), respectively.<br \/>\n      Treatment-experienced patients who received elbasvir\/grazoprevir with or<br \/>\n      without RBV for 16 or 18 weeks achieved virologic cure rates of 100<br \/>\n      percent (49\/49) and 94 percent (46\/49), respectively. These data will be<br \/>\n      presented during an oral presentation at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aasld.org%2Fevents-professional-development%2Fliver-meeting&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=The+Liver+Meeting%C2%AE&amp;index=1&amp;md5=180ea686c56eda26c45761814c2a1008\" rel=\"nofollow\">The<br \/>\n      Liver Meeting<sup>\u00ae<\/sup><\/a> (Abstract #42).\n    <\/p>\n<p>\n      \u201cPatients with chronic hepatitis C virus infection and compensated<br \/>\n      cirrhosis have historically been difficult to treat because their<br \/>\n      bodies\u2019 ability to respond to antiviral therapy is compromised,\u201d said<br \/>\n      Dr. Ira Jacobson, site chair, department of medicine, Mount Sinai Beth<br \/>\n      Israel, New York. \u201cIn this integrated analysis of data from multiple<br \/>\n      trials, patients treated with elbasvir\/grazoprevir were able to achieve<br \/>\n      high virologic cure rates, often without the addition of ribavirin.\u201d\n    <\/p>\n<p>\n      The integrated analysis included patients with compensated liver<br \/>\n      cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials,<br \/>\n      the individual results of which have been previously presented: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fmerck-announces-results-phase-2-study-investigational-chronic-he-0&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=C-WORTHy&amp;index=2&amp;md5=6397271affde14e9dc2df1758d5a5101\" rel=\"nofollow\"><i>C-WORTHy<\/i><\/a><i>,<br \/>\n      <\/i><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fresults-mercks-phase-3-study-investigational-chronic-hepatitis-c-t&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=C-SURFER&amp;index=3&amp;md5=c7170c4134a0a16c04180a4022931bf9\" rel=\"nofollow\"><i>C-SURFER<\/i><\/a><i>,<br \/>\n      <\/i><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fmercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevirelbasv&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=C-EDGE+TN&amp;index=4&amp;md5=da95683a05b2f7546a495e98b0c29350\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      TN<\/i><\/a><i>, <\/i><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fmercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevirelbasv&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=C-EDGE+CO-INXFN&amp;index=5&amp;md5=b73197603737532dfa3700c2a1de1667\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      CO-INXFN<\/i><\/a><i>, <\/i><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fmercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevirelbasv&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=C-EDGE+TE&amp;index=6&amp;md5=5f0e3d92341ed9026674e1537680f84e\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      TE<\/i><\/a> and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fmerck-announces-presentation-phase-2-clinical-trial-results-invest&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=C-SALVAGE&amp;index=7&amp;md5=ee5175010d7b3fd95d91c3bb3eaca6b1\" rel=\"nofollow\"><i>C-SALVAGE<\/i><\/a>.<br \/>\n      The analysis evaluated the efficacy and safety of investigational<br \/>\n      once-daily elbasvir\/grazoprevir with or without RBV for 12 weeks in<br \/>\n      treatment-na\u00efve patients (n=169) and 12 and 16 or 18 weeks in<br \/>\n      treatment-experienced patients (n=233). Of the treatment-experienced<br \/>\n      patients, 64 percent (150\/233) were prior non-responders, 21 percent<br \/>\n      (49\/233) were prior relapsers and 15 percent (34\/233) were previously<br \/>\n      treated with HCV NS3\/4A protease inhibitors (simeprevir, telaprevir and<br \/>\n      boceprevir).\n    <\/p>\n<p>\n      Two sets of patients were analyzed. In the FAS, the assessment included<br \/>\n      all randomized patients who received at least one dose of drug (n=402).<br \/>\n      The integrated analysis also assessed a modified full analysis set<br \/>\n      (mFAS) (n=398) that excluded four patients who discontinued treatment<br \/>\n      for reasons unrelated to the study drug: one treatment-na\u00efve patient on<br \/>\n      12 weeks of elbasvir\/grazoprevir without RBV; two treatment-experienced<br \/>\n      patients on 12 weeks of elbasvir\/grazoprevir without RBV; and one<br \/>\n      treatment-experienced patient on 12 weeks of elbasvir\/grazoprevir with<br \/>\n      RBV. Compensated cirrhosis was determined by one of the following<br \/>\n      methods: liver biopsy, FibroScan, AST to platelet ratio or FibroTest.\n    <\/p>\n<p>\n      <b>Summary of SVR12 Findings: FAS<\/b>\n    <\/p>\n<p>\n      <b>Table 1<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n          <b>Treatment-Na\u00efve<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"7\">\n          <b>Treatment-Experienced<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Without RBV<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=138)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>With RBV<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=31)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Without RBV<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=54)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>With RBV<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=81)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Without RBV<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=49)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>With RBV<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=49)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Duration<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(Weeks)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          12\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          12\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          12\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          12\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          16 or 18\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          16 or 18\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>All Patients<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            98%\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (135\/138)*\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          90%<\/p>\n<p class=\"bwcellpmargin\">\n            (28\/31)<sup>\u2020<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          89%<\/p>\n<p class=\"bwcellpmargin\">\n            (48\/54)<sup>\u00a7<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            91%<br \/>(74\/81)<sup>\u2021<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            94%\n          <\/p>\n<p class=\"bwcellpmargin\">\n            (46\/49)<sup>#<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            100%<br \/>(49\/49)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      * Virologic failure occurred in one percent (2\/138) of patients<br \/>\n      including one breakthrough and one relapse.\n    <\/p>\n<p>\n      <sup>\u2020<\/sup> Virologic failure occurred in 10 percent (3\/31) of patients<br \/>\n      including one breakthrough and two relapses.\n    <\/p>\n<p>\n      <sup>\u00a7<\/sup> Virologic failure occurred in seven percent (4\/54) of<br \/>\n      patients including four relapses.\n    <\/p>\n<p>\n      <sup>\u2021<\/sup> Virologic failure occurred in seven percent (6\/81) of<br \/>\n      patients including six relapses.\n    <\/p>\n<p>\n      <sup>#<\/sup> Virologic failure occurred in six percent (3\/49) of<br \/>\n      patients including two rebounds and one relapse.\n    <\/p>\n<p>\n      <b>Summary of SVR12 Findings: mFAS<\/b><sup><b>2<\/b><\/sup>\n    <\/p>\n<p>\n      <b>Table 2a<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"10\">\n          <b>Treatment-Na\u00efve<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"10\">\n          <b>Without RBV (n=137)*<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Duration (Weeks)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"10\">\n          <b>12<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>All Patients<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"10\">\n          99% (135\/137)**\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" rowspan=\"3\">\n          <b>Genotype<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT1a<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT1b<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT4<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT6<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          97%<\/p>\n<p class=\"bwcellpmargin\">\n            (73\/75)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100%<\/p>\n<p class=\"bwcellpmargin\">\n            (56\/56)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100%<\/p>\n<p class=\"bwcellpmargin\">\n            (6\/6)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          &#8211;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      * In the additional population of treatment na\u00efve patients administered<br \/>\n      elbasvir\/grazoprevir with RBV for 12 weeks, 90% (28\/31) achieved SVR12.\n    <\/p>\n<p>\n      ** Virologic failure occurred in one percent (2\/137) of patients<br \/>\n      including one breakthrough and one relapse.\n    <\/p>\n<p>\n      <b>Table 2b<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"15\">\n          <b>Treatment-Experienced<\/b><sup>\u2020<\/sup>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"7\">\n          <b>Without RBV (n=52)*<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"7\">\n          <b>With RBV (n=49)**<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Duration (Weeks)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"7\">\n          <b>12<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"7\">\n          <b>16 or 18<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>All Patients<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"7\">\n          92% (48\/52)***\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"7\">\n          100% (49\/49)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" rowspan=\"2\">\n          <b>Genotype<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT1<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT4<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT6<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT1<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT4<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>GT6<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          94%<\/p>\n<p class=\"bwcellpmargin\">\n            (44\/47)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          80%<\/p>\n<p class=\"bwcellpmargin\">\n            (4\/5)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8211;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100%<\/p>\n<p class=\"bwcellpmargin\">\n            (44\/44)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100%<\/p>\n<p class=\"bwcellpmargin\">\n            (4\/4)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100%<\/p>\n<p class=\"bwcellpmargin\">\n            (1\/1)\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      \u2020 Prior null response, partial response or relapse with pegylated<br \/>\n      interferon\/RBV\n    <\/p>\n<p>\n      * In the additional population of treatment-experienced patients<br \/>\n      administered elbasvir\/grazoprevir with RBV for 12 weeks, 93% (74\/80)<br \/>\n      achieved SVR12.\n    <\/p>\n<p>\n      ** In the additional population of treatment-experienced patients<br \/>\n      administered elbasvir\/grazoprevir without RBV for 16 or 18 weeks, 94%<br \/>\n      (46\/49) achieved SVR12.\n    <\/p>\n<p>\n      *** Virologic failure occurred in eight percent (4\/52) of patients<br \/>\n      including four relapses.\n    <\/p>\n<p>\n      The most common adverse events (AEs) reported in patients who received<br \/>\n      elbasvir\/grazoprevir, or elbasvir\/grazoprevir with RBV, and placebo<br \/>\n      were: fatigue (15%, 31% and 18%, respectively), headache (17%, 21% and<br \/>\n      14%, respectively) and nausea (4%, 14% and 14%, respectively). One<br \/>\n      serious drug-related AE occurred in a patient taking<br \/>\n      elbasvir\/grazoprevir due to severe abdominal pain without associated<br \/>\n      symptoms. Seven patients discontinued due to treatment-related AEs (two<br \/>\n      patients taking elbasvir\/grazoprevir; four patients taking<br \/>\n      elbasvir\/grazoprevir with RBV; and one patient taking placebo).\n    <\/p>\n<p>\n      <b>About Elbasvir\/Grazoprevir<\/b>\n    <\/p>\n<p>\n      Elbasvir\/grazoprevir is Merck\u2019s investigational, once-daily, fixed-dose<br \/>\n      combination therapy containing elbasvir (HCV NS5A replication complex<br \/>\n      inhibitor) and grazoprevir (HCV NS3\/4A protease inhibitor). Merck\u2019s<br \/>\n      broad clinical trials program includes evaluations of<br \/>\n      elbasvir\/grazoprevir with or without ribavirin for multiple HCV<br \/>\n      genotypes, together with patients with difficult-to-treat conditions,<br \/>\n      such as cirrhosis, advanced chronic kidney disease, HIV\/HCV<br \/>\n      co-infection, inherited blood disorders and those on opioid agonist<br \/>\n      therapy. In July 2015, the U.S. Food and Drug Administration (FDA)<br \/>\n      granted Priority Review for the New Drug Application for<br \/>\n      elbasvir\/grazoprevir with a Prescription Drug User Fee Act (PDUFA)<br \/>\n      action date of Jan. 28, 2016.\n    <\/p>\n<p>\n      In April 2015, the FDA granted Breakthrough Therapy Designation for<br \/>\n      elbasvir\/grazoprevir for the treatment of patients with chronic HCV GT1<br \/>\n      infection with end stage renal disease on hemodialysis, and Breakthrough<br \/>\n      Therapy Designation for elbasvir\/grazoprevir for the treatment of<br \/>\n      patients with chronic HCV GT4 infection. Breakthrough Therapy<br \/>\n      Designation is intended to expedite the development and review of a<br \/>\n      candidate that is planned for use, alone or in combination, to treat a<br \/>\n      serious or life-threatening disease or condition when preliminary<br \/>\n      clinical evidence indicates that the drug may demonstrate substantial<br \/>\n      improvement over existing therapies on one or more clinically<br \/>\n      significant endpoints.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For nearly 30 years, Merck has been at the forefront of the response to<br \/>\n      the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to deliver innovative<br \/>\n      healthcare solutions that support people living with HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=8&amp;md5=40584b6a2fcf6e82e662e878c800353a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=Twitter&amp;index=9&amp;md5=674e903660568fcc2ed789036d3d455a\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=Facebook&amp;index=10&amp;md5=4705787a1e12874459d7aee784dfc7b8\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=YouTube&amp;index=11&amp;md5=c08e7847aa2c2131332880203995e425\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=12&amp;md5=5f24f2745cb06f8103b1067c0989cc47\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51224922&amp;newsitemid=20151114005028&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=13&amp;md5=7ffd05f5746f7540690e086bd8b4decb\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Elbasvir is an HCV NS5A replication complex inhibitor and<br \/>\n      grazoprevir is an HCV NS3\/4A protease inhibitor.\n    <\/p>\n<p>\n      <sup>2<\/sup> Data presented in Tables 2a and 2b include regimens by<br \/>\n      treatment population with the highest rates of SVR or comparable SVR<br \/>\n      without the addition of RBV.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151114005028r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>or<br \/>Sarra Herzog,        201-669-6570<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir\/grazoprevir 1 (50mg\/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from the full analysis set (FAS) (n=402) demonstrate that treatment-na\u00efve patients with compensated liver cirrhosis who received elbasvir\/grazoprevir with or without RBV for 12 weeks achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, or virologic cure) at rates of 90 percent (28\/31) and 98 percent (135\/138), respectively. Treatment-experienced patients who received elbasvir\/grazoprevir with or without RBV for 12 weeks achieved virologic cure rates of 91 percent (74\/81) and<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745076","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir\/grazoprevir 1 (50mg\/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from the full analysis set (FAS) (n=402) demonstrate that treatment-na\u00efve patients with compensated liver cirrhosis who received elbasvir\/grazoprevir with or without RBV for 12 weeks achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, or virologic cure) at rates of 90 percent (28\/31) and 98 percent (135\/138), respectively. Treatment-experienced patients who received elbasvir\/grazoprevir with or without RBV for 12 weeks achieved virologic cure rates of 91 percent (74\/81) and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\\\/\",\"name\":\"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\\\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-11-15T00:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\\\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir\/grazoprevir 1 (50mg\/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from the full analysis set (FAS) (n=402) demonstrate that treatment-na\u00efve patients with compensated liver cirrhosis who received elbasvir\/grazoprevir with or without RBV for 12 weeks achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, or virologic cure) at rates of 90 percent (28\/31) and 98 percent (135\/138), respectively. Treatment-experienced patients who received elbasvir\/grazoprevir with or without RBV for 12 weeks achieved virologic cure rates of 91 percent (74\/81) and","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:48+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/","name":"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-11-15T00:00:00+00:00","dateModified":"2025-11-07T06:24:48+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-trials-evaluating-investigational-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-4-or-6-infectio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir\/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ffe0d2e1-87bf-45da-8115-0cccdf32dcff","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-to-Release-Findings-from-Integrated-Analysis-of-Six-Phase-2-and-3-Clinical-Trials-Evaluating-Investigational-ElbasvirGrazoprevi-1G0WJ.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745076\/revisions"}],"predecessor-version":[{"id":3674572,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745076\/revisions\/3674572"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745076"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}